The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study
Abstract
AIMS: The aim of this study was to investigate serious clinical outcomes associated with atrial fibrillation (AF) and the effects of routine blood pressure lowering on such outcomes in the presence or absence of AF, among individuals with type 2 diabetes. METHODS AND RESULTS: About 11 140 patients with type 2 diabetes (7.6% of whom had AF at baseline) were randomized to a fixed combination of perindopril and indapamide or placebo in the Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study. We compared total mortality and cardiovascular disease outcomes and effects of randomized treatment for 4.3 years on such outcomes between patients with and without AF at baseline. After multiple adjustments, AF was associated with a 61% (95% confidence interval 31-96, P < 0.0001) greater risk of all-cause mortality and comparable higher risks of cardiovascular death, stroke, and heart failure (all P < 0.001). Routine treatment with a fixed combination of perindopril and indapamide produced similar relative, but greater absolute, risk reductions for all-cause and cardiovascular mortalities in patients with AF, compared with those without AF. The number of patients needed to be treated with perindopril-indapamide for 5 years to prevent one cardiovascular death was 42 for patients with AF and 120 for patients without AF at baseline. CONCLUSION: Atrial fibrillation is relatively common in type 2 diabetes and is associated with substantially increased risks of death and cardiovascular events in patients with type 2 diabetes. This arrhythmia identifies individuals who are likely to obtain greater absolute benefits from blood pressure-lowering treatment. Atrial fibrillation in diabetic patients should be regarded as a marker of particularly adverse outcome and prompt aggressive management of all risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hence, AF in patients with diabetes should be viewed as a marker of adverse outcome, which should prompt aggressive management of all concomitant risk factors.609”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [609]
In the citing paper
“Diabetes and AF frequently coexist because of associations with other risk factors.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [278]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · cited 1×
“4% in 2030.(1) People with diabetes have at least twice the risk of vascular complications and cardiovascular death, compared with those without diabetes.”
BackgroundImpact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study
Benjamin, E. J., Wolf, P. A., D’Agostino, R. B., Silbershatz, H., Kannel, W. B., & Levy, D. (1998) · Circulation · doi:10.1161/01.cir.98.10.946 · Cited by 4,575 · cited 1×
“In the Framingham cohort, the excess risk of all-cause mortality associated with new-onset AF was 50% in men and 90% in women.(18) The greater risk of cardiovascular death associated with AF in women compared with men could not be explained by differences in age, cardiovascular risk factors, or use of concomitant trea…”
BackgroundEpidemiologic Features of Chronic Atrial Fibrillation: The Framingham Study
Kannel, W. B., Abbott, R. D., Savage, D. D., & McNamara, P. M. (1982) · New England Journal of Medicine · doi:10.1056/nejm198204293061703 · Cited by 2,314 · cited 1×
“In general population studies, the presence of AF is associated with increased risks of stroke, thrombo-embolism, heart failure, and cardiovascular death.(7,8) Treatment with anticoagulants and blood pressurelowering agents are known to ameliorate these risks.”
BackgroundPatel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054 · cited 1×
“The ADVANCE study showed that routine administration of perindopril and indapamide in the treatment of patients with diabetes produced worthwhile benefits in preventing cardiovascular outcomes, regardless of the initial blood pressure level.(23) Consistent with previous studies,(10,14) patients with AF derived similar…”
ResultSelf-citationHuxley, R., Barzi, F., & Woodward, M. (2006) · BMJ · doi:10.1136/bmj.38678.389583.7c · Cited by 1,534 · cited 1×
“People with diabetes have at least twice the risk of vascular complications and cardiovascular death, compared with those without diabetes.(2,3) Prevention of vascular complications is a major goal in the management of patients with diabetes.”
BackgroundSelf-citationWachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826 · cited 1×
“055).(20) Evidence that AF confers a hypercoagulable state—and is closely related to generalized atherothrombotic risk and atherosclerosis per se—is consistent with these and our findings.”
ResultSwedberg, K., Olsson, L. G., Charlesworth, A., Cleland, J., Hanrath, P., Komajda, M., Metra, M., Torp-Pedersen, C., & Poole-Wilson, P. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi166 · Cited by 647 · cited 3×
“This divergence may be explained by the more common use of anticoagulants and (multiple) blood pressure-lowering agents in patients with heart failure than in those with uncomplicated hypertension.(13,14) The level of anticoagulant use in ADVANCE was low, albeit comparable with that described in contemporary community…”
ResultFang, M. C., Singer, D. E., Chang, Y., Hylek, E. M., Henault, L. E., Jensvold, N. G., & Go, A. S. (2005) · Circulation · doi:10.1161/circulationaha.105.553438 · Cited by 469 · cited 2×
“This has previously been observed in non-diabetic populations, in which studies have reported greater risks associated with AF for stroke and cardiovascular mortality in women, compared with men.(8,17) In the Framingham cohort, the excess risk of all-cause mortality associated with new-onset AF was 50% in men and 90%…”
ResultMovahed, M.-R., Hashemzadeh, M., & Mazen Jamal, M. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.02.050 · Cited by 379 · cited 2×
“Atrial fibrillation is a relatively common arrhythmia in people with diabetes.(5,6) The prevalence of AF in ADVANCE is consistent with .”
Background
Research works printed but not linked: 1
- 2004, Diabetes Care, 21, 1047
Cited by
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P. E., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 9,971
Self-citationWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citation
Metadata
- Authors
- Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., Poulter, N., Lip, G. Y. H., Patel, A., & on behalf of the ADVANCE Collaborative Group
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- The University of Melbourne (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- Imperial College London (GB)
- Birmingham City Hospital (GB)
- Corresponding author
- Patel, A.
- ORCID
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-11
- Volume
- 30
- Issue
- 9
- Pages
- 1128-1135
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2128136679
- Cited by
- 239
- References
- 27
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 12 · 2023: 12 · 2022: 19 · 2021: 25 · 2020: 17 · 2019: 16 · 2018: 17 · 2017: 12 · 2016: 17 · 2015: 18 · 2014: 12 · 2013: 12 · 2012: 10
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- atrial fibrillation, type 2 diabetes, blood pressure reduction, perindopril, indapamide, ADVANCE trial, cardiovascular mortality, stroke, heart failure, all-cause mortality, cardiovascular risk, antihypertensive therapy
- MeSH terms
- Aged, Antihypertensive Agents, Atrial Fibrillation, Blood Glucose, Diabetic Angiopathies, Drug Therapy, Combination, Female, Humans, Hypertension, Indapamide, Male, Middle Aged, Risk Factors, Confidence Intervals, Treatment Outcome, Perindopril
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. https://app.cochat.ai/papers/10.1093/eurheartj/ehp055
- The paper
- Du, X., Ninomiya, T., de Galan, B., Abadir, E., Chalmers, J., Pillai, A., Woodward, M., Cooper, M., Harrap, S., Hamet, P., Poulter, N., Lip, G. Y. H., Patel, A., & on behalf of the ADVANCE Collaborative Group. (2009). Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehp055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.